BACKGROUND: Chronic pulmonary infection with transmissible Pseudomonas aeruginosa strains in individuals with cystic fibrosis (CF) has been reported, raising issues of cross infection and patient segregation. The first such strain to be described (the Liverpool epidemic strain, LES) is now widespread in many UK CF centres. However, whether such infection carries a worse prognosis is unknown. To address this, the clinical course of a group of CF patients chronically infected by LES was compared with that in patients harbouring unique strains. METHODS: Using P aeruginosa strain genotyping, two cohorts of CF patients attending the Liverpool CF service were identified who were LES positive or negative in 1998 and remained so until 2002. From these, two groups of 12 patients were matched in 1998 for age, spirometric parameters, and nutritional state and their clinical course was followed for 5 years. Patients chronically infected with Burkholderia cepacia were excluded. RESULTS: Patients chronically infected with LES had a greater annual loss of lung function than those not chronically infected by LES (mean difference between groups -4.4% (95% CI -8.1 to -0.9; p<0.02)), and by 2002 their percentage predicted forced expiratory volume in 1 second (FEV1) was worse (mean 65.0% v 82.6%, p<0.03). Their nutritional state also deteriorated over the study period (mean difference between groups in body mass index -0.7 (95% CI -1.2 to -0.2; p<0.01)), such that by 2002 they were malnourished compared with LES negative patients (mean BMI 19.4 v 22.7, p<0.02). CONCLUSIONS: Chronic infection with the Liverpool epidemic P aeruginosa strain in CF patients confers a worse prognosis than infection with unique strains alone, confirming the need for patient segregation. Since this strain is common in many CF units, strain identification in all CF centres is essential. This can only be carried out using genomic typing methods.
BACKGROUND:Chronic pulmonary infection with transmissible Pseudomonas aeruginosa strains in individuals with cystic fibrosis (CF) has been reported, raising issues of cross infection and patient segregation. The first such strain to be described (the Liverpool epidemic strain, LES) is now widespread in many UK CF centres. However, whether such infection carries a worse prognosis is unknown. To address this, the clinical course of a group of CF patients chronically infected by LES was compared with that in patients harbouring unique strains. METHODS: Using P aeruginosa strain genotyping, two cohorts of CF patients attending the Liverpool CF service were identified who were LES positive or negative in 1998 and remained so until 2002. From these, two groups of 12 patients were matched in 1998 for age, spirometric parameters, and nutritional state and their clinical course was followed for 5 years. Patients chronically infected with Burkholderia cepacia were excluded. RESULTS:Patients chronically infected with LES had a greater annual loss of lung function than those not chronically infected by LES (mean difference between groups -4.4% (95% CI -8.1 to -0.9; p<0.02)), and by 2002 their percentage predicted forced expiratory volume in 1 second (FEV1) was worse (mean 65.0% v 82.6%, p<0.03). Their nutritional state also deteriorated over the study period (mean difference between groups in body mass index -0.7 (95% CI -1.2 to -0.2; p<0.01)), such that by 2002 they were malnourished compared with LES negative patients (mean BMI 19.4 v 22.7, p<0.02). CONCLUSIONS:Chronic infection with the Liverpool epidemic P aeruginosa strain in CF patients confers a worse prognosis than infection with unique strains alone, confirming the need for patient segregation. Since this strain is common in many CF units, strain identification in all CF centres is essential. This can only be carried out using genomic typing methods.
Authors: K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart Journal: Lancet Date: 1996-09-07 Impact factor: 79.321
Authors: A Abdul Wahab; S J Taj-Aldeen; F Hagen; S Diophode; A Saadoon; J F Meis; C H Klaassen Journal: Eur J Clin Microbiol Infect Dis Date: 2013-09-01 Impact factor: 3.267
Authors: Urszula Wnorowska; Katarzyna Niemirowicz; Melissa Myint; Scott L Diamond; Marta Wróblewska; Paul B Savage; Paul A Janmey; Robert Bucki Journal: Antimicrob Agents Chemother Date: 2015-04-13 Impact factor: 5.191
Authors: Ruth Ann Luna; Laura A Millecker; C Renee Webb; Sally K Mason; Elaine M Whaley; Jeffrey R Starke; Peter W Hiatt; James Versalovic Journal: J Clin Microbiol Date: 2013-01-09 Impact factor: 5.948
Authors: Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley Journal: Microbiologyopen Date: 2013-11-11 Impact factor: 3.139
Authors: V Waters; J E A Zlosnik; Y C W Yau; D P Speert; S D Aaron; D S Guttman Journal: Eur J Clin Microbiol Infect Dis Date: 2012-07-29 Impact factor: 3.267
Authors: Akinobu Kamei; Andrew Y Koh; Mihaela Gadjeva; Gregory P Priebe; Stephen Lory; Gerald B Pier Journal: J Infect Dis Date: 2010-01-01 Impact factor: 5.226
Authors: Craig Winstanley; Morgan G I Langille; Joanne L Fothergill; Irena Kukavica-Ibrulj; Catherine Paradis-Bleau; François Sanschagrin; Nicholas R Thomson; Geoff L Winsor; Michael A Quail; Nicola Lennard; Alexandra Bignell; Louise Clarke; Kathy Seeger; David Saunders; David Harris; Julian Parkhill; Robert E W Hancock; Fiona S L Brinkman; Roger C Levesque Journal: Genome Res Date: 2008-12-01 Impact factor: 9.043